Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Drug Profile

Research programme: transdermal therapeutics - Aequus Pharmaceuticals

Alternative Names: AQS 1302; AQS 1303

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antiemetics; Antiepileptic drugs
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Epilepsy; Nausea

Most Recent Events

  • 02 Mar 2017 Aequus Pharmaceuticals enters into a binding term sheet agreement for worldwide exclusive license of cannabinoid transdermal patch for Neurological disorders
  • 18 Nov 2016 Aequus Pharmaceuticals plans a proof-of-concept study for Nausea and Vomiting of pregnancy in Canada
  • 05 Aug 2016 Research programme: transdermal therapeutics - Aequus Pharmaceuticals is available for licensing in World as of 05 Aug 2016. http://www.aequuspharma.ca/en/index.htm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top